Tocilizumab-Anoh
- Biologic
- Prescription only
- Identity checked
- Sources last checked 2026-09-04
This page shows what was measured, who it was measured in, and what that does not settle.
RNAWiki holds very little about this substance. The page shows what there is.
What Tocilizumab-Anoh does in the body
1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
Tocilizumab products bind to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been shown to be involved in diverse physiological processes such as T-cell activation, induction of immunoglobulin secretion, initiation of hepatic acute phase protein synthesis, and stimulation of hematopoietic precursor cell proliferation and differentiation. IL-6 is also produced by synovial and endothelial cells leading to local production of IL-6 in joints affected by inflammatory processes such as rheumatoid arthritis.
Why people take it. AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
- Where it acts
- Not recorded.
- Kind of result
- No result is published, so no kind of result applies yet
- Supervision
- Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
Where each sentence above came from
The use the label states, quoted from it. No plain-language version of this sentence has been written.
The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.
No statement of the main limit is recorded.
The four opening statements run to 180 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Formulation
A formulation is the exact made-up form a substance comes in.
A picture of it, and where the picture fails
It is like the difference between a whole bean and instant coffee.
Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.
What people get wrong. Two products with the same name are assumed to behave the same. They often do not.
The specific composition and physical form of a product, including salt, excipients and release profile.
What is missing or unclearRead from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
- Moderately to severely active rheumatoid arthritis who have had an inadequate respon
Who is missing from the studies
- Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “AVTOZMA by subcutaneous use is indicated for the treatment of pediatric patients with: Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older Active systemic juvenile idiopathic arthritis in patients 2 years of age and older The safety and effectiveness of AVTOZMA in pediatric patients with conditions other than PJIA, SJIA or CRS have not been established.”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
On older people, the label states: “Clinical studies that included tocilizumab for CRS did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary The available data with tocilizumab products from a pregnancy exposure registry, retrospective cohort study, pharmacovigilance, and published literature are insufficient to draw conclusions about a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary No information is available on the presence of tocilizumab products in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production.”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
On people with reduced liver function, the label states: “The safety and efficacy of tocilizumab products have not been studied in patients with hepatic impairment, including patients with positive HBV and HCV serology [see Warnings and Precautions (5.8) ] .”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
On people with reduced kidney function, the label states: “No dose adjustment is required in patients with mild or moderate renal impairment.”
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
Where the result stopped carrying
- This is a scope explorer, not a diagnosis engine.
- It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to takeRead from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The studied form is not the form on the shelf.
On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
- It was studied for a different goal
- The studies measured something else entirely. Nothing in this record points to this reason.
- There was nothing to correct
- Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
- Something else had to happen too
- In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
- The change is too small to feel
- A real change can still sit below what a person notices. Nothing in this record points to this reason.
- Day-to-day swing hides it
- Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
- Not enough time yet
- The studies ran longer than the person has waited. Nothing in this record points to this reason.
- It was not taken as studied
- Missed days change the result, and studies count them. Nothing in this record points to this reason.
- Something else changed at the same time
- Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
- The product may not be what it says
- Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
- No recorded reason
- RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to takeRead from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No form or route is recorded.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S6.
No source is stored against this line.
What is in the pack
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing is recorded about product quality.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to takeNothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclearRead from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
The exact form studied is not recorded.
No source is stored against this line.
What is sold
Not recorded.
Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
AVTOZMA is intravenous at 3 DOSAGE FORMS AND STRENGTHS Intravenous Infusion Injection: 80 mg/4 mL (20 mg/mL), 200 mg/10 mL (20 mg/mL), 400 mg/20 mL (20 mg/mL) in single-dose vials for further dilution prior to intravenous infusion ( 3 ) Subcutan…, recorded as fda label in effect 2026-07-27 in the United States.
US prescribing information · 581c288f-8015-40ef-a4c3-683c96db193d · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
Names and forms linked to this record
Biosimilar of
Evidence on this page does not automatically apply to this one.
What it would be like to takeRead from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
- Which of the trials of Tocilizumab-Anoh studied people like me?
- What was measured, and for how long?
- Was the result a laboratory value or a health outcome?
- What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclearRead from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Tocilizumab-Anoh are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in peopleNothing found in the sources checked
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Nothing found in the sources checked
No traced study record is stored for this substance.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Checks this page had to pass
Passed
Identity resolved
no open identity hold
Passed
No unresolved merge across substance families
no quarantine open
Passed
Every public sentence names a source
The opening statement carries the origin: Quoted from a stored source.
Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
Passed
Safety mode resolved
Suppression classes recorded: S6.
Passed
Canonical metadata present
slug and display name present
What is missing or unclearRead from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
2 approved applications cover products containing this substance. The earliest was BLA761420, approved 20250124 to CELLTRION INC.
Drugs@FDA application register · BLA761420 · read 2026-08-29
Marketing status on the register: prescription.
Drugs@FDA application register · BLA761420 · read 2026-08-29
What is missing or unclearRead from sources, not yet reviewed
What to learn next
Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.
- Were people like me actually studied?
- How close is this evidence to something I would notice?
- What does nobody know about this yet?
- What is a formulation?
This order is fixed in code and does not count clicks or time on the page.
What is not here
10 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
- What was measured, goal by goal — found nothing in the sources checked.
- What happened in people — found nothing in the sources checked.
- How close this is to real life — found nothing in the sources checked.
- The path through the body — found nothing in the sources checked.
- Felt, measured, or meaningful — found nothing in the sources checked.
- How long anything takes — found nothing in the sources checked.
- What it may clash with — found nothing in the sources checked.
- Other ways to the same goal — found nothing in the sources checked.
- Claims that go past the evidence — found nothing in the sources checked.
- What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (8)
On the Tocilizumab-Anoh label: indicated for what?
"AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell…": indications and usage on Tocilizumab-Anoh's label. DailyMed label · 581c288f-8015-40ef-a4c3-683c96db193d · 2026-08-30
133 registered trials of Tocilizumab-Anoh — at which phases?
- Registered studies posting no result
- 79 of 133
133 registered studies of Tocilizumab-Anoh: 54 phase2, 35 phase1, 28 phase3, 14 na or unstated, 12 phase4, 3 na, 2 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
0 with a PubMed record
Show the evidence
- phase254
- phase135
- phase328
- na or unstated14
- phase412
- na3
8 more recorded rows
- early phase12
- completed66
- terminated19
- recruiting15
- active not recruiting14
- unknown11
- withdrawn7
- not yet recruiting1
recorded 2026-09-01 · last checked 2026-09-04
24 of Tocilizumab-Anoh's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?
safety (3), futility/efficacy (1), accrual/recruitment (9), funding/business (4) and other (7): Tocilizumab-Anoh's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"Tocilizumab was licenced in Canada for children, so the study was not necessary"; 24 of 133 registered studies
Show the evidence
Trial
- NCT01104480withdrawn; "Tocilizumab was licenced in Canada for children, so the study was not necessary"
- NCT01209689terminated; "Clinical development program terminated due to failure to achieve efficacy"
- NCT01475162terminated; "The DSMB felt the risks of the study now outweighed the potential benefits."
- NCT01603355terminated; "insufficient enrollment"
- NCT01693653terminated; "low enrollment"
- NCT01757197terminated; "Slow accrual"
14 further recorded trials
- NCT02057770terminated; "Low accrual rate"
- NCT02174263withdrawn; "Study never opened due to lack of funds."
- NCT02353780terminated; "Low enrollment"
- NCT02511067withdrawn; "Funding lost and study never started"
- NCT02659150terminated; "Terminated by sponsor owing to slow enrollment"
- NCT02660528terminated; "Study staff change."
- NCT02997956withdrawn; "funding issues"
- NCT03588936terminated; "Poor accrual and loss of funding."
- NCT04070781terminated; "The primary reason for study closure is slow enrollment."
- NCT04335071terminated; "1.) Not possible to recruit the planned number of patients during the planned study period; 2.) "Dexamethason" was included in the standard of care for the study population during the course of the study and inclusion criteria could no…"
- NCT04335305terminated; "Recruitment issues"
- NCT04361552withdrawn; "Study abandoned due to drug billing issues"
- NCT04370834terminated; "Other - Randomized data no longer support continuation"
- NCT04403685terminated; "Safety"
recorded 2026-09-01 · last checked 2026-09-04
Human studies of Tocilizumab-Anoh used Tocilizumab 20 MG/ML [Actemra] — over how long?
studies of Tocilizumab-Anoh used the recorded amount. ClinicalTrials.gov · 2026-09-01
1 recorded entry; human; also "Tocilizumab 20 MG/ML [Actemra]"
Show the evidence
- human NCT06426160Tocilizumab 20 MG/ML [Actemra]
recorded 2026-09-01 · last checked 2026-09-04
Tocilizumab-Anoh's half-life is 21.5 days — which schedules were studied?
21.5 days, the half-life Tocilizumab-Anoh's label states: "At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates." DailyMed label · 581c288f-8015-40ef-a4c3-683c96db193d · 2026-08-30
bioavailability 80% %.
Show the evidence
- half life recorded_background.pharmacokinetics21.5 days; At high serum concentrations, when total clearance of tocilizumab is dominated by linear clearance, a terminal half-life of approximately 21.5 days was derived from the population parameter estimates.
- bioavailability recorded_background.pharmacokinetics80% %; The bioavailability for the subcutaneous formulation was 80%.
recorded 2026-08-30 · last checked 2026-09-04
Which 22 trials of Tocilizumab-Anoh posted no result?
- Posted no result
- 22 of 22 completed trials
- Registrations
- NCT01120366, NCT02797769, NCT01455701, NCT03062579, NCT02648035 and NCT03522012, and 16 more
- Completion dates
- oldest 2014-12; newest 2024-06-11
Show the evidence
Trial
- NCT011203662014-12
- NCT027977692016-06-02
- NCT014557012017-07-13
- NCT030625792018-05-15
- NCT026480352018-12-20
- NCT035220122018-12-20
14 further recorded trials
- NCT035331012019-06-15
- NCT036068762019-07-17
- NCT033506332019-09-01
- NCT032828512019-10-01
- NCT032637152020-06-02
- NCT048731412020-06-22
- NCT034462092020-10-30
- NCT038302032021-01-05
- NCT053029472021-06-30
- NCT047346782021-08-01
- NCT045513522022-07-28
- NCT064812022022-08-19
- NCT048718542022-08-26
- NCT048858292023-05-04
At the median, Tocilizumab-Anoh's trials enrolled 50 people — anything larger?
- Median enrolment
- 50
- Largest enrolment
- 48950
- Registered trials counted
- 133
Tocilizumab-Anoh and CYP3A4, CYP1A2 and CYP2C19: shared by which compounds?
CYP3A4, CYP1A2 and CYP2C19 appear in Tocilizumab-Anoh's recorded interaction sentences, 8 in all. DailyMed label · 581c288f-8015-40ef-a4c3-683c96db193d · 2026-08-30
CYP1A2, CYP2B6, CYP2C19, CYP2C19, CYP2C8, CYP2C9; 12 shared nodes; pharmacokinetics
Show the evidence
Interaction statement
- pharmacokineticsDrug Interaction Studies In vitro data suggested that IL-6 reduced mRNA expression for several CYP450 isoenzymes including CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and this reduced expression was reversed by co-incubation with tocilizumab at clinically relevant concentrations.
- pharmacokineticsOmeprazole Omeprazole is a CYP2C19 and CYP3A4 substrate.
- pharmacokineticsIts effect on CYP2C8 or transporters (e.g., P-gp) is unknown.
- pharmacokineticsDextromethorphan Dextromethorphan is a CYP2D6 and CYP3A4 substrate.
- pharmacokineticsSelection of a particular dose of simvastatin in RA patients should take into account the potentially lower exposures that may result after initiation of AVTOZMA (due to normalization of CYP3A4) or higher exposures after discontinuation of AVTOZMA.
- pharmacokineticsCaution should be exercised when AVTOZMA is coadministered with drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives (CYP3A4 substrates) [see Drug Interactions (7.2) ] .
2 more recorded rows
- Interaction statement pharmacokineticsSimvastatin Simvastatin is a CYP3A4 and OATP1B1 substrate.
- Interaction statement pharmacokineticsHowever, exposure to its metabolite, dextrorphan (a CYP3A4 substrate), was a fraction of that observed in healthy subjects.
- CYP1A2FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Golodirsen, Tinidazole
- CYP2B6FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Sofpironium, Bupropion, Golodirsen, Tinidazole, Naldemedine
CYP2C19
- FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Naldemedine, Etravirine
- FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Naldemedine, Etravirine
- CYP2C8FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Golodirsen, Naldemedine, Methylnaltrexone, Lapatinib, Tivozanib
- CYP2C9FINGOLIMOD LAURYL SULFATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Golodirsen, Tinidazole, Naldemedine
CYP2D6
- FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine
- FINGOLIMOD LAURYL SULFATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Rasagiline, Sofpironium, Fluoxetine
CYP3A4
- FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
- FINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Beclometasone, Rasagiline, Sofpironium
- OATP1B1FINGOLIMOD LAURYL SULFATE, TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Deoxycholic acid, Golodirsen, Naldemedine, Eravacycline
- P-gpFINGOLIMOD LAURYL SULFATE, ERYTHROMYCIN LACTOBIONATE, Darunavir Propylene Glycolate, FOSAPREPITANT DIMEGLUMINE, TAFAMIDIS MEGLUMINE, Arimoclomol, Ceftobiprole Medocaril, Vincristine
recorded 2026-08-30 · last checked 2026-09-04
Where it is registered
Identifiers, relations and other names
The exact record
- UNII
- I031V2H011
- CAS number
- 375823-41-9
- RxCUI
- 612865
Relations
- Biosimilar of Tocilizumab
- Trade name
- Avtozma, ACTEMRA
- Also called
- ATLIZUMAB, IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN INTERLEUKIN 6 RECEPTOR) (HUMAN-MOUSE MONOCLONAL MRA HEAVY CHAIN), DISULPHIDE WITH HUMAN-MOUSE MONOCLONAL MRA .KAPPA.-CHAIN, DIMER, MRA
- Development code
- BAT-1806, BAT1806, BIIB-800, BIIB800, MSB-11456, MSB11456
Sources (5)
Sources
- CLINICALTRIALS_SNAPSHOT K1:I031V2H011#anoh ·
- ClinicalTrials.gov clinicaltrials.gov ·
- drugsfda+ema drugsfda+ema ·
- DailyMed label 581c288f-8015-40ef-a4c3-683c96db193d ·
- Drugs@FDA K1:I031V2H011#anoh ·
ClinicalTrials.gov — US Government work · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
How these records are assembled · Which registers were checked
Index-quality checks
- identity passed: no open identity hold
- required summary fields resolved: 3 required field(s) not terminal: Best-supported result, Biggest unanswered question, Human evidence
- public claims reviewed: 0 reviewed claim(s); drafts are never rendered
- source coverage passed: 5 source rows
- no critical contamination: no quarantine open
- canonical metadata passed: slug and display name present
- no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.